Literature DB >> 334679

Plasma levels of di-no-propylacetate and clonazepam in epileptic patients.

A Baruzzi, B Bordo, L Bossi, D Castelli, M Gerna, G Tognoni, P Zagnoni.   

Abstract

Plasma levels of DPA and CNP and associated antiepileptic drugs were measured in groups of respectively 106 and 30 epileptic patients aged from 3 to 49 years. A poor correlation between daily oral dose and plasma levels of both drug was observed when the whole group of patients was considered. A better correlation was seen in a group of adult patients who received DPA and PB. Children below 10 years of age disposed both drugs faster than adults and the difference was significant (p less than 0.01) in groups receiving PB as associated drug. Patients medicated with PB and DPA or CNP showed lower plasma levels of both drugs; on the other hand DPA appeared to cause a decrease of PB clearance which was more marked in children. The clinical significance of the fluctuations of daily plasma levels of both drugs are discussed in relationship to the schedule of administration and plasma sampling. Observations on the therapeutic ranges and adverse effect of the drugs are reported.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 334679

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Biopharm        ISSN: 0340-0026


  9 in total

Review 1.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of valproic acid.

Authors:  R Gugler; G E von Unruh
Journal:  Clin Pharmacokinet       Date:  1980 Jan-Feb       Impact factor: 6.447

3.  Clonazepam in neonatal seizures: dose regimens and therapeutic efficacy.

Authors:  M André; M J Boutroy; G Bianchetti; P Vert; P L Morselli
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Diurnal variations in steady-state plasma concentrations of valproic acid in epileptic patients.

Authors:  P Loiseau; B Cenraud; R H Levy; R Akbaraly; A Brachet-Liermain; M Guyot; P L Morselli
Journal:  Clin Pharmacokinet       Date:  1982 Nov-Dec       Impact factor: 6.447

5.  Some clinical pharmacological aspects of n-dipropylacetamide.

Authors:  F Pisani; R Di Perri
Journal:  Ital J Neurol Sci       Date:  1980-10

6.  Clonazepam pharmacokinetics and therapeutic efficacy in neonatal seizures.

Authors:  M André; M J Boutroy; C Dubruc; J P Thenot; G Bianchetti; L Sola; P Vert; P L Morselli
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex.

Authors:  Todd M Conner; Vahagn C Nikolian; Patrick E Georgoff; Manjunath P Pai; Hasan B Alam; Duxin Sun; Ronald C Reed; Tao Zhang
Journal:  Eur J Pharm Sci       Date:  2017-10-10       Impact factor: 4.384

8.  A serious adverse drug reaction probably induced by clonazepam: a case report of myotoxicity.

Authors:  Xiaonian Han; Jinping Wang
Journal:  BMC Pharmacol Toxicol       Date:  2019-11-05       Impact factor: 2.483

9.  A Case Report of Clonazepam Dependence: Utilization of Therapeutic Drug Monitoring During Withdrawal Period.

Authors:  Ivana Kacirova; Milan Grundmann; Petr Silhan; Hana Brozmanova
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.